Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736695 · ClinicalTrials.gov registry record · Phase 1
Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT02736695: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT02736695 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02736695, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.
Interventions
- DRUG F-18 AV 1451
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2016-07 |
| Est. Completion | 2024-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02736695
The ClinicalTrials.gov registry entry for NCT02736695 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which F-18 AV 1451 is the first listed.
NCT02736695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02736695 about?
NCT02736695 is a clinical study titled "Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia". This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.
What is the current status of trial NCT02736695?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2016-07. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT02736695?
The interventions under investigation include: F-18 AV 1451 (DRUG).
Who is sponsoring clinical trial NCT02736695?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.